<DOC>
	<DOCNO>NCT02507635</DOCNO>
	<brief_summary>The main purpose treatment persistent allergic rhinitis improve symptom patient ' quality life prevent development asthma . Therapeutic strategy also target reduction pro-inflammatory mediator release activated cell , include mast cell epithelial cell . The presence allergic inflammation nasal mucosa may increase risk asthma occurrence , especially patient persistent allergic rhinitis . H1 antihistamines widely recommend type allergic rhinitis , regardless symptom severity persistence . They control symptom , less extent nasal congestion . New generation agent , levocetirizine desloratadine , possess anti-inflammatory property , reduce allergic inflammation .</brief_summary>
	<brief_title>Anti-inflammatory H1 Antihistamines Allergic Rhinitis</brief_title>
	<detailed_description>Allergic rhinitis characterize chronic inflammation nasal mucosa represent risk factor asthma occurrence . H1 antihistamines reduce rhinitis ' symptom , compound may anti-inflammatory property . We evaluate plasmatic level cytokine patient persistent allergic rhinitis ( PAR ) evolution 4-week treatment H1 antihistamine risk asthma 1.5 year . Eighty-five patient PAR 30 healthy volunteer include study . The patient PAR randomly divide 2 group : 41 patient treat desloratadine 5 mg/day 44 patient levocetirizine 5 mg/day 4 week . The clinical evaluation include presence severity allergic rhinitis ' symptom : rhinorrhea , nasal congestion , sneeze , nasal ocular itch duration disease . Each symptom evaluate scale 0 3 ( 0=absent , 1=mild , 2=moderate , 3=severe ) calculate total symptom score ( TSS ) . A TSS &lt; 6 mean mild rhinitis , TSS &gt; 6 represent moderate severe one . The patient clinically evaluate 1.5 year determine possible onset bronchial asthma . The biological evaluation mean determination total IgE plasmatic level IL-1 beta , IL-6 , IL-8 TNF alpha . Clinical biological evaluation perform treatment</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Desloratadine</mesh_term>
	<mesh_term>Levocetirizine</mesh_term>
	<mesh_term>Cetirizine</mesh_term>
	<mesh_term>Histamine Antagonists</mesh_term>
	<mesh_term>Histamine H1 Antagonists</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>persistent allergic rhinitis presence asthma nasal polyp , acute chronic upper respiratory infection , administration intranasal systemic corticosteroid H1 antihistamine past 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>cytokine</keyword>
	<keyword>persistent allergic rhinitis</keyword>
	<keyword>H1 antihistamine</keyword>
</DOC>